Results 241 to 250 of about 209,848 (307)
Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown +2 more
wiley +1 more source
Survival strategies of mycoplasmas: the critical role of post-translational modifications. [PDF]
Li T, Yuan H, Zhang W, Guo F.
europepmc +1 more source
Targeting protein–protein interactions with reversible covalent modalities: Non‐cysteine chemistries
Abstract Protein–protein interactions (PPIs) are central to diverse cellular functions, and represent a rapidly expanding class of therapeutic targets. Advancements in covalent drug design have enabled small‐molecule drugs to overcome challenges associated with engaging these targets, such as limited durations of action and difficult‐to‐drug (expansive,
Ruchira Basu, Steven Fletcher
wiley +1 more source
The stress-activated kinase p38 mediates non-canonical activation of Src and tyrosine phosphorylation of the adapter protein TAB1. [PDF]
Onuma I +15 more
europepmc +1 more source
TSP4 is upregulated in human and experimental AAA. TSP4 knockdown accelerated AAA formation and exacerbated both vascular inflammation and remodelling, emphasizing that TSP4 upregulation may represent a protective response against AAA. Our findings suggest that preserving TSP4 could be a useful strategy in the clinical management of AAA.
Laia Blanco‐Casoliva +10 more
wiley +1 more source
Cellular phospho-signaling map of the enigmatic serine/threonine kinase MAST2. [PDF]
Fathima I +7 more
europepmc +1 more source
This study identifies downregulated autoantibodies in NSCLC and demonstrates their diagnostic and prognostic utility. Integrating proteome‐wide screening and large‐cohort validation, we highlight a novel biomarker class that enhances early detection and patient stratification.
Yihao Liang +7 more
wiley +1 more source
Revealing and Exploiting the Biochemistry of <i>O</i>-GlcNAc through Protein Semisynthesis. [PDF]
Ampomah GB, Pratt MR.
europepmc +1 more source
Reversal of MPPa‐PDT Resistance in Osteosarcoma by Targeting ROCK2‐Mediated Autophagy
ROCK2 competes with MST1 to bind to the aa 28‐198 region of SAV1 and then regulates the Hippo pathway to affect autophagy, resulting in the resistance of OS to MPPa‐PDT. Targeted inhibition of ROCK2 by screening for J059‐0149 increases the sensitivity of osteosarcoma to MPPa‐PDT. ABSTRACT Osteosarcoma (OS) is a primary bone tumour that occurs mostly in
Xuan Yi +14 more
wiley +1 more source

